“The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange.”
Read the full story at biospace.com
What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ
- Braincheck Raises Another $1.5 Million to Bring Artificial Intelligence to Dementia Care | PR Web